Literature DB >> 24161765

NF-κB, ERK, p38 MAPK and JNK contribute to the initiation and/or maintenance of mechanical allodynia induced by tumor necrosis factor-alpha in the red nucleus.

Qian Zhang1, Jing Wang, Mei-Ting Duan, Shui-Ping Han, Xiao-Yan Zeng, Jun-Yang Wang.   

Abstract

Previous studies have demonstrated that tumor necrosis factor-alpha (TNF-α) in the red nucleus (RN) plays facilitated roles in the development of abnormal pain. Here, the roles of nuclear factor-kappa B (NF-κB), extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) in TNF-α-evoked mechanical allodynia were investigated. Repeated microinjection of recombinant rat TNF-α (20 ng daily for 3 days) into the unilateral RN of normal rats induced a significant mechanical allodynia in the contralateral but not ipsilateral hind paw at the fifth day and disappeared 24h later. Re-injection of a single bolus of 20 ng TNF-α into the same RN reproduced this mechanical allodynia within 30 min, which was used as a pain model for further experiments. Immunohistochemistry demonstrated that NF-κB, phospho-ERK (p-ERK) and p-p38 MAPK in the RN were significantly up-regulated at 1h after TNF-α microinjection, the up-regulations of NF-κB and p-ERK but not p-p38 MAPK remained at high levels till 4h later. A significant up-regulation of p-JNK occurred at 4h (but not 1h) after TNF-α microinjection, which was later than those of NF-κB, p-ERK and p-p38 MAPK. Pre-treatment with NF-κB inhibitor PDTC, ERK inhibitor PD98059 or p38 MAPK inhibitor SB203580 at 30 min before TNF-α microinjected into the RN completely prevented TNF-α-evoked mechanical allodynia. Pre-treatment with JNK inhibitor SP600125 did not prevent but reversed TNF-α-evoked mechanical allodynia during the subsequent detection time. Post-treatment with PDTC, PD98059 or SP600125 (but not SB203580) at 4h after TNF-α microinjected into the RN significantly reversed TNF-α-evoked mechanical allodynia. These results further prove that TNF-α in the RN plays a crucial role in the development of abnormal pain, and the algesic effect of TNF-α is initiated through activating NF-κB, ERK and p38 MAPK. The later maintenance of TNF-α-evoked mechanical allodynia mainly relies on the activation of NF-κB, ERK and JNK, but not p38 MAPK.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DRG; ERK; IL; JNK; LTP; Mitogen-activated protein kinase; NF-κB; NGF; Nuclear factor-kappa B; PDTC; PWT; RN; RVM; Rat; Red nucleus; SNI; TNF-α; Tumor necrosis factor-alpha; c-Jun N-terminal kinase; dorsal root ganglia; extracellular signal-regulated kinase; interleukin; long-term potentiation; nerve growth factor; nuclear factor-kappa B; p38 MAPK; p38 mitogen-activated protein kinase; paw withdrawal threshold; pyrrolidine dithiocarbamate; red nucleus; rostral ventromedial medulla; spared nerve injury; tumor necrosis factor-alpha

Mesh:

Substances:

Year:  2013        PMID: 24161765     DOI: 10.1016/j.brainresbull.2013.10.008

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  12 in total

1.  The Red Nucleus Interleukin-6 Participates in the Maintenance of Neuropathic Pain Induced by Spared Nerve Injury.

Authors:  Cui-Ping Ding; Yu-Shun Xue; Jing Yu; Yi-Jie Guo; Xiao-Yan Zeng; Jun-Yang Wang
Journal:  Neurochem Res       Date:  2016-08-03       Impact factor: 3.996

2.  Infliximab relieves blood retinal barrier breakdown through the p38 MAPK pathway in a diabetic rat model.

Authors:  Mao-Song Xie; Yong-Zheng Zheng; Li-Bin Huang; Guo-Xing Xu
Journal:  Int J Ophthalmol       Date:  2017-12-18       Impact factor: 1.779

3.  The Red Nucleus TNF-α Participates in the Initiation and Maintenance of Neuropathic Pain Through Different Signaling Pathways.

Authors:  Qian Zhang; Jing Yu; Jing Wang; Cui-Ping Ding; Shui-Ping Han; Xiao-Yan Zeng; Jun-Yang Wang
Journal:  Neurochem Res       Date:  2015-05-08       Impact factor: 3.996

4.  Effects of portulacerebroside a on apoptosis of human leukemia HL60 cells and p38/JNK signaling pathway.

Authors:  Qidong Ye; Na Zhang; Kai Chen; Jiashi Zhu; Hui Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 5.  Current gene therapy using viral vectors for chronic pain.

Authors:  Jean-Marc G Guedon; Shaogen Wu; Xuexing Zheng; Caroline C Churchill; Joseph C Glorioso; Ching-Hang Liu; Shue Liu; Lucy Vulchanova; Alex Bekker; Yuan-Xiang Tao; Paul R Kinchington; William F Goins; Carolyn A Fairbanks; Shuanglin Hao
Journal:  Mol Pain       Date:  2015-05-13       Impact factor: 3.395

6.  PD98059 Influences Immune Factors and Enhances Opioid Analgesia in Model of Neuropathy.

Authors:  Ewelina Rojewska; Katarzyna Popiolek-Barczyk; Natalia Kolosowska; Anna Piotrowska; Magdalena Zychowska; Wioletta Makuch; Barbara Przewlocka; Joanna Mika
Journal:  PLoS One       Date:  2015-10-01       Impact factor: 3.240

7.  μ-Opioid activation in the midbrain during migraine allodynia - brief report II.

Authors:  Thiago D Nascimento; Marcos F DosSantos; Sarah Lucas; Hendrik van Holsbeeck; Misty DeBoer; Eric Maslowski; Tiffany Love; Ilkka K Martikainen; Robert A Koeppe; Yolanda R Smith; Jon-Kar Zubieta; Alexandre F DaSilva
Journal:  Ann Clin Transl Neurol       Date:  2014-06-01       Impact factor: 4.511

8.  The analgesic effect of rolipram is associated with the inhibition of the activation of the spinal astrocytic JNK/CCL2 pathway in bone cancer pain.

Authors:  Chi-Hua Guo; Lu Bai; Huang-Hui Wu; Jing Yang; Guo-Hong Cai; Xin Wang; Sheng-Xi Wu; Wei Ma
Journal:  Int J Mol Med       Date:  2016-09-30       Impact factor: 4.101

9.  Antagonism of Protease-Activated Receptor 4 Protects Against Traumatic Brain Injury by Suppressing Neuroinflammation via Inhibition of Tab2/NF-κB Signaling.

Authors:  Jianing Luo; Xun Wu; Haixiao Liu; Wenxing Cui; Wei Guo; Kang Guo; Hao Guo; Kai Tao; Fei Li; Yingwu Shi; Dayun Feng; Hao Yan; Guodong Gao; Yan Qu
Journal:  Neurosci Bull       Date:  2020-10-27       Impact factor: 5.203

10.  Overexpression of KLF5 inhibits puromycin‑induced apoptosis of podocytes.

Authors:  Yang Li; Xiaoni Sui; Xueqing Hu; Zhao Hu
Journal:  Mol Med Rep       Date:  2018-08-09       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.